MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Syneron Medical wins FDA 510(k) for short-wavelength PicoWay laser

Syneron Medical wins FDA 510(k) for short-wavelength PicoWay laser

By

Syneron CandelaSyneron Medical said today it won FDA 510(k) clearance for a new ultra-short 785nm wavelength laser for its PicoWay picosecond laser device.

The PicoWay system is an aesthetic laser system designed for removing tattoos of all colors and types and treating pigmented lesions. The system won FDA clearance for the removal of tattoos in November, 2014 and for the treatment of pigmented lesions in April, 2015.

The company touts the device as the 1st of its kind to win such clearance for the aesthetic market. The new ultra-short 785nm wavelength laser uses a titanium sapphire laser for the removal of blue and green inks.

“This is the 1st, ever, 785nm wavelength picosecond-domain laser in the world. This novel addition to the PicoWay enables optimal treatment for blue and green tattoos, and is a welcome addition to the 532 and 1,064nm wavelengths already available with the PicoWay. I am extremely impressed with Jay Bhawalkar and his engineering team at Candela, who developed the PicoWay. The new 785nm wavelength further enhances the already strong capabilities of the PicoWay platform for tattoo removal, adding to its ability to rapidly and safely clear multicolored tattoos. I am thrilled to offer this new wavelength to my patients, and honored to have lead the clinical trial leading to FDA clearance of the PicoWay and this new wavelength,” principal investigator Dr. Eric Bernstein of Philadelphia’s Main Line Center for Laser Surgery said in a press release.

Syneron said it plans to make the device available in the U.S. in the 4th quarter of this year to new and existing PicoWay customers.

“We are pleased to receive FDA clearance for the new 785nm wavelength for PicoWay, which enhances its ability to remove blue and green tattoo ink. With the addition of this third wavelength, PicoWay can now provide practices with the ability to provide comprehensive removal and treatment of all colors of tattoos and skin pigmentation. We look forward to making this feature available to new and existing PicoWay customers in the U.S. beginning in the fourth quarter,” CEO Amit Meridor said in prepared remarks.

In case you missed it

RSS From Medical Design & Outsourcing

  • Keep the end in mind when choosing a medtech partner
    There are five general categories of medtech vendor partners. If the end is apparent in the beginning, the correct type of partner will be more apparent. Jim Reed, Minnetronix Medical Stephen Covey gave the business world this mantra in one of his bestsellers: “Start with the end in mind.” Whether they didn’t read the book… […]
  • Orthofix launches Fiberfuse Strip bone graft
    Orthofix (NSDQ:OFIX) today announced that it has launched its FiberFuse Strip bone graft in the U.S. Lewisville, Texas–based Orthofix designed the FiberFuse Strip to be a preformed bone-graft strip for posterior cervical, posterior lumbar and degenerative spinal procedures. FiberFuse Strip is 100% bone and has a unique mixture of mineralized cancellous and demineralized cortical bone with… […]
  • Thermo Fisher Scientific beats The Street in Q2 results
    Thermo Fisher Scientific (NYSE:TMO) today posted second-quarter results that beat the overall consensus on Wall Street. The Waltham, Mass.–based company reported profits of $1.8 billion, or $4.61 per share, on sales of $9.3 billion for the three months ended July 1, 2021, for a bottom-line gain of 58.1% on sales growth of 34.1% compared with… […]
  • Choosing the Right Rubber Material and Process for Your Medical Parts
    When it’s time to design and develop a new medical device that calls for an elastomer component, there are a number of material options and manufacturing processes to consider. The long list of material properties impacting performance includes your prospective polymer’s end-use environment, chemical compatibility, hardness, compression set, tensile properties and manufacturability — to name… […]
  • 3M’s healthcare segment registers growth in Street-beating Q2
    3M (NYSE:MMM) reported second-quarter results that beat the consensus forecast — with the company’s healthcare segment showing especially robust growth. The St. Paul, Minn.–based company posted profits of $1.5 billion, or $2.59 per share, on sales of $9 billion for the three months ended June 30, 2021, for a 16.7% bottom-line gain on sales growth of… […]
  • Evren Technologies earbud PTSD treatment device nabs FDA breakthrough device designation
    Evren Technologies this week announced that it received FDA breakthrough device designation for its Phoenix earbud device that treats PTSD. Gainesville, Fla.-based Evren Technologies designed the Phoenix device as a discreet earbud design that delivers transcutaneous auricular vagal nerve stimulation in a closed-loop system. It can be paired with the company’s PTSD symptom tracking app… […]
  • BD acquires resorbable polymer maker Tepha
    BD (NYSE:BDX) today announced that it has acquired resorbable polymer technology maker Tepha for an undisclosed amount. Franklin Lakes, N.J.–based BD said that it will use Lexington, Mass.–based Tepha’s resorbable polymer technology to accelerate growth of the company’s surgical mesh for soft tissue repair, reconstruction and regeneration. Tepha’s GalaFlex portfolio is also included in the acquisition.… […]
  • LifeSignals remote patient monitor wins FDA clearance
    LifeSignals today announced that it has received FDA 510(k) clearance for its LX1550 multi-parameter remote monitoring platform. Fremont, Calif.–based LifeSignals designed the LX1550 to continuously collect patient physiological data from home and in healthcare settings. The platform has a single-use wearable multi-parameter biosensor that records electrocardiography (ECG), heart rate, respiration rate, skin temperature and body… […]
  • Blackrock Neurotech and ClearPoint Neuro want to automate brain implant surgeries
    ClearPoint Neuro (NSDQ:CLPT) announced an agreement with Blackrock Neurotech to develop automated technologies for brain implant surgeries. The partnership will seek to develop an automated surgical solution for implanting brain-computer interfaces (BCIs) into patients with neurological disorders — including from paralysis, ALS, blindness and hearing loss. Solana Beach, Calif.–based ClearPoint Neuro said in a news… […]
  • New Mountain Capital to acquire Flexan
    New Mountain Capital’s ILC Dover today announced that it has reached a definitive agreement to acquire Flexan for an undisclosed amount. Lincolnshire, Ill.–based Flexan is a contract design and manufacturing company specializing in high-precision silicone, rubber and thermoplastic components for the medical device industry. The acquisition will allow both companies to serve a broader client… […]
  • How COVID-19 changed medical device clinical trials forever
    The success of remote clinical trial oversight opens the door to hybrid approaches and creates new possibilities for the future of trials. DeviceTalks Because of the pandemic, virtually overnight, all players involved in medical device clinical trials had to pivot to virtual monitoring to keep trials going. What impact did remote trial oversight have on… […]